{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:20Z","timestamp":1791388100332,"version":"4.3.3"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejca.2022.07.006","type":"journal-article","created":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T18:02:01Z","timestamp":1660240921000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"174","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5757-6161","authenticated-orcid":false,"given":"Cho-Han","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7910-2338","authenticated-orcid":false,"given":"Cho-Hung","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yu","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan Ping","family":"Hsia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5388-9112","authenticated-orcid":false,"given":"Xin Ya","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0909-1776","authenticated-orcid":false,"given":"Chuan-Sheng","family":"Horng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Er","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Syuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien-Chi","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Sheng-Kai","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5068-9457","authenticated-orcid":false,"given":"Brian Shiian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-7183","authenticated-orcid":false,"given":"Yu-Ze","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8392-3342","authenticated-orcid":false,"given":"Soon-Tzeh","family":"Tay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Hsuan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4834-4406","authenticated-orcid":false,"given":"Katharine Ching","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cho-Hsien","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Ming","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6382","key":"10.1016\/j.ejca.2022.07.006_bib1","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ejca.2022.07.006_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2021.09.013","article-title":"Combining immune checkpoint inhibitors with chemotherapy in advanced solid tumours: a review","volume":"158","author":"Larroquette","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.07.006_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejca.2022.07.006_bib4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejca.2021.08.004","article-title":"Current strategies for intratumoural immunotherapy \u2013 beyond immune checkpoint inhibition","volume":"157","author":"Yuan","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.006_bib5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41392-020-00213-8","article-title":"Overcoming cancer therapeutic bottleneck by drug repurposing","volume":"5","author":"Zhang","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.006_bib6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001361","article-title":"Integrated analysis of concomitant medications and oncological outcomes from PD-1\/PD-L1 checkpoint inhibitors in clinical practice","volume":"8","author":"Cortellini","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.07.006_bib7","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2021.12.024","article-title":"Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors","volume":"163","author":"Drobni","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.07.006_bib8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2020.09.033","article-title":"Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index","volume":"142","author":"Buti","year":"2021","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.006_bib9","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ccell.2021.11.002","article-title":"The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1","volume":"40","author":"Li","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2022.07.006_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ebiom.2016.06.013","article-title":"Repurposing cationic amphiphilic antihistamines for cancer treatment","volume":"9","author":"Ellegaard","year":"2016","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejca.2022.07.006_bib11","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ejca.2021.08.036","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.07.006_bib12","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ccr.2013.08.003","article-title":"Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase","volume":"24","author":"Petersen","year":"2013","journal-title":"Cancer Cell"},{"issue":"9","key":"10.1016\/j.ejca.2022.07.006_bib13","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1158\/1535-7163.MCT-18-1406","article-title":"Cell death induced by cationic amphiphilic drugs depends on lysosomal Ca(2+) release and cyclic AMP","volume":"18","author":"Anand","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.ejca.2022.07.006_bib14","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jnci\/djz217","article-title":"Antihistamines and ovarian cancer survival: nationwide cohort study and in\u00a0vitro cell viability assay","volume":"112","author":"Verdoodt","year":"2020","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.ejca.2022.07.006_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101029","article-title":"Improved survival in several cancers with use of H(1)-antihistamines desloratadine and loratadine","volume":"14","author":"Fritz","year":"2021","journal-title":"Transl Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.07.006_bib16","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1007\/s12325-019-00970-1","article-title":"Generating real-world tumor burden endpoints from electronic health record data: comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer","volume":"36","author":"Griffith","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.ejca.2022.07.006_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/CCI.18.00155","article-title":"An exploratory analysis of real-world end points for assessing outcomes among immunotherapy-treated patients with advanced non-small-cell lung cancer","volume":"3","author":"Stewart","year":"2019","journal-title":"JCO Clin Cancer Inform"},{"issue":"12","key":"10.1016\/j.ejca.2022.07.006_bib18","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1093\/aje\/kwj149","article-title":"Variable selection for propensity score models","volume":"163","author":"Brookhart","year":"2006","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.ejca.2022.07.006_bib19","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/sim.6004","article-title":"A comparison of 12 algorithms for matching on the propensity score","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.ejca.2022.07.006_bib20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes","volume":"22","author":"Freeman-Keller","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.006_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"10","key":"10.1016\/j.ejca.2022.07.006_bib22","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/ijc.28873","article-title":"Risk of cancer in patients with medically diagnosed hay fever or allergic rhinitis","volume":"135","author":"Hemminki","year":"2014","journal-title":"Int J Cancer"},{"issue":"11","key":"10.1016\/j.ejca.2022.07.006_bib23","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-020-03140-2","article-title":"PD-L1 degradation pathway and immunotherapy for cancer","volume":"11","author":"Gou","year":"2020","journal-title":"Cell Death Dis"},{"issue":"43","key":"10.1016\/j.ejca.2022.07.006_bib24","doi-asserted-by":"crossref","first-page":"E10119","DOI":"10.1073\/pnas.1802166115","article-title":"Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1)","volume":"115","author":"Kowanetz","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.006_bib25","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the american heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"10.1016\/j.ejca.2022.07.006_bib26","article-title":"Angiotensin converting enzyme (ACE) inhibitors versus angiotensin receptor blockers for primary hypertension","volume":"2014","author":"Li","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ejca.2022.07.006_bib27","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2165\/00002018-200124020-00003","article-title":"Safety of antihistamines in children","volume":"24","author":"Ten Eick","year":"2001","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.ejca.2022.07.006_bib28","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2500\/108854100778249033","article-title":"Safety of second generation antihistamines","volume":"21","author":"Philpot","year":"2000","journal-title":"Allergy Asthma Proc"},{"issue":"11","key":"10.1016\/j.ejca.2022.07.006_bib29","article-title":"Antihistamines for the common cold","author":"De Sutter","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.ejca.2022.07.006_bib30","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.2018.5690","article-title":"Trends in prescription medication use among children and adolescents-United States, 1999-2014","volume":"319","author":"Hales","year":"2018","journal-title":"JAMA"},{"issue":"4 Suppl.","key":"10.1016\/j.ejca.2022.07.006_bib31","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0091-6749(03)01876-1","article-title":"H1-Antihistamines: more relevant than ever in the treatment of allergic disorders","volume":"112","author":"Simons","year":"2003","journal-title":"J Allergy Clin Immunol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004269?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922004269?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:17Z","timestamp":1760733377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922004269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"alternative-id":["S0959804922004269"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.006","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}